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ABSTRACT
Antibodies that target cell-surface molecules on T cells can enhance anti-tumor 
immune responses, resulting in sustained immune-mediated control of cancer. We 
set out to find new cancer immunotherapy targets by phenotypic screening on human 
regulatory T (Treg) cells and report the discovery of novel activators of tumor necrosis 
factor receptor 2 (TNFR2) and a potential role for this target in immunotherapy. A 
diverse phage display library was screened to find antibody mimetics with preferential 
binding to Treg cells, the most Treg-selective of which were all, without exception, 
found to bind specifically to TNFR2. A subset of these TNFR2 binders were found to 
agonise the receptor, inducing iκ-B degradation and NF-κB pathway signalling in vitro. 
TNFR2 was found to be expressed by tumor-infiltrating Treg cells, and to a lesser 
extent Teff cells, from three lung cancer patients, and a similar pattern was also 
observed in mice implanted with CT26 syngeneic tumors. In such animals, TNFR2-
specific agonists inhibited tumor growth, enhanced tumor infiltration by CD8+ T cells 
and increased CD8+ T cell IFN-γ synthesis. Together, these data indicate a novel 
mechanism for TNF-α-independent TNFR2 agonism in cancer immunotherapy, and 
demonstrate the utility of target-agnostic screening in highlighting important targets 
during drug discovery.
INTRODUCTION
Immune-mediated cancer therapies, particularly 
monoclonal antibodies (mAbs) that target cell-surface 
receptors expressed by T cells, are rapidly emerging as a 
valuable class of cancer drugs. Clinical data indicate that 
antagonists of cytotoxic T lymphocyte antigen 4 (CTLA-4) 
and programmed cell death protein 1/programmed death-
ligand 1 (PD-1/PD-L1) can lead to durable anti-tumor 
immune responses [1–5], and have led to widespread 
interest in targeting other T cell surface antigens, including 
co-stimulatory members of the tumor necrosis factor 
receptor superfamily (TNFRSF) such as OX40 and 4-1BB 
(CD137) [6, 7]. In addition to enhancing the activation 
of effector T (Teff) cells, it may also be useful to inhibit 
regulatory T (Treg) cells or other immuno-suppressive cell 
populations within tumors [8]. Indeed, Treg modulation 
may contribute towards the efficacy of certain cancer 
therapies. For example, recent mechanistic studies indicate 
the anti-CCR4 mAb mogamulizumab, approved for the 
treatment of relapsed adult T cell leukemia (ATL) in 
Japan [9], could reduce the number of Treg cells in cancer 
patients [10]. Meta-analysis of clinical data indicates that 
increased CD8+ Teff/Treg ratios correlate to improved 
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prognosis in multiple cancer types [11]. Identifying novel 
drug targets expressed by Teff and/or Treg cells will allow 
for novel drug combinations, and ultimately may lead 
to enhanced clinical response rates and bring significant 
benefit to patient populations that currently fail to respond 
to existing therapies [12].
The search for a unique cell-surface marker that 
reproducibly identifies human or mouse Treg populations 
has been challenging. As such, Tregs are currently 
categorised by the expression of two cell surface markers, 
CD4 and CD25 [13], and the intracellular transcription 
factor Foxp3 [14]. Previous attempts have been made 
to identify novel Treg surface markers using unbiased 
antibody screening of hybridomas from mice immunised 
with human Treg cells [15]. However, despite extensive 
screening, the antibodies isolated from this Treg 
immunisation approach were only able to identify existing, 
known markers such as CD25 and MHC class II, which on 
their own have limited Treg selectivity.
Our previous work has shown that phage display 
enrichment of diverse antibody libraries by panning on 
cells, followed by antibody screening for selective binding 
or desired function can be an effective, target-agnostic 
approach to identify novel markers and indeed therapeutic 
targets [16–18]. We have also demonstrated that phage 
display may have advantages over hybridoma-based 
screening, due to the ability to rationally deselect antibodies 
to known or abundant antigens, therefore enabling access to 
wider pools of targets during the screening process [17, 18].
For these reasons, we employed a target-agnostic 
phage display screening approach on human Treg cells to 
find antibody mimetics with preferential binding to Treg, 
rather than Teff, cells. For optimal performance during 
the phage display step we used designed ankyrin repeat 
proteins (DARPins) [19–22], antibody mimetics which are 
particularly suitable for cell-based selections, due to high 
levels of display on phage [18]. To our surprise, all of the 
most selective DARPins prioritised from this screen were 
found to bind specifically to tumor necrosis factor receptor 
2 (TNFR2, TNFRSF1B), a receptor for membrane-bound 
TNF-α [23]. Some of the DARPins were found to also 
agonise TNFR2, activating the NF-κB signalling pathway 
in primary human Treg cells and Jurkat T cells transfected 
with TNFR2. Furthermore, we demonstrated, using mouse-
reactive TNFR2-specific agonists, that we could enhance 
anti-tumor immunity in the CT26 syngeneic tumor model. 
Together these data provide support for TNFR2-specific 
agonists as potential cancer immunotherapy drugs.
RESULTS
Target-agnostic screening for human Treg cell 
selectivity
To identify Treg cell-surface proteins by phage 
display affinity selections, highly pure populations of 
human CD4+CD25+ Treg cells were isolated from healthy 
donor peripheral blood as described in Materials and 
Methods (Figure 1A) [24]. Purity was assessed by staining 
for Foxp3 (Supplementary Figure S1A) and Treg phenotype 
confirmed using in vitro suppression assays (Supplementary 
Figure S1B). Phage display cell affinity selections were 
performed using a DARPin library, de-selecting using a 
panel of recombinant T cell markers (listed in Materials 
and Methods). The selection output following two rounds of 
selections was sub-cloned, and sequencing identified 1843 
unique DARPin clones from a total population of 2816 
clones sequenced (65% sequence diversity). The binding of 
the 1843 unique potential Treg binding DARPins, expressed 
as mouse IgG2a Fc fusion proteins, to activated human Treg 
and CD4+ Teff cells was investigated using high-throughput 
microscopy and flow cytometry (Figure 1A–1C). A group 
of 56 DARPins were identified that bound to Treg and not 
to activated CD4+CD25- Teff cells; from these a group of 26 
DARPins were deprioritised due to their binding activated 
human NK cells, B cells, monocytes, or broad populations 
of cells amongst human peripheral blood leukocytes. 
Finally, thirty DARPins were identified (hereafter referred 
to as TREG001 to TREG030), which bound selectively to 
activated human Treg cells.
DARPins bind to TNFR2
To investigate epitope redundancy amongst the 
thirty Treg-binding DARPins, TREG001 and TREG002 
were arbitrarily chosen and each was labelled with biotin 
and used to stain Treg cells following pre-incubation 
with unlabelled samples of each of the thirty DARPins 
of interest (Supplementary Figure S2). In every case, pre-
incubation reduced the extent of biotinylated TREG001 
and TREG002 binding to Treg cells, indicating that the 
thirty DARPins bound to the same antigen. To identify 
this antigen, TREG001, TREG002, and six others were 
tested for binding to a membrane protein expression 
library array. The DARPins were observed to bind to 
cells expressing TNFRSF1B, which encodes TNFR2. This 
result was then confirmed using a limited panel of genes 
including TNFRSF1B, genes encoding Fcγ receptors, and 
a protein for which non-specific binding is frequently 
observed (RASGRP1; Figure 2A).
To further confirm TNFR2 was the target antigen 
for the Treg DARPins, activated Treg cells were incubated 
with goat anti-human TNFR2 polyclonal antibodies 
(pAb), which were observed to result in loss of binding 
by DARPins (Supplementary Figure S3A). DARPins 
TREG005 and TREG006 were then chosen for more 
detailed analysis, on the basis of high staining intensity, 
high yields following transient transfections, and low levels 
of aggregation in solution (data not shown). TREG005 and 
TREG006 bound to recombinant TNFR2 but not to TNFR1, 
TNFR3, or osteoprotegerin, which has high sequence 
similarity to TNFR2 (Supplementary Figure S3B).
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Characterising the interaction between DARPins 
and TNFR2
TREG005 and TREG006 were observed to 
bind to Treg cells with half-maximal binding at 
concentrations of ~100 pM and 10 pM respectively (EC50 
values; Supplementary Figure S3C) and to constructs 
incorporating the third and fourth extracellular cysteine-
rich domains of TNFR2, but not to a TNFR2 construct 
lacking these domains (Supplementary Figure S4A, S4B). 
Binding of TNFR2 to immobilised TREG005 and 
TREG006 was abrogated by pre-incubation of TNFR2 
with TNF-α (Figure 2B), and binding to immobilised 
TNF-α was reduced by pre-incubation with TREG005 and 
TREG006 but not control DARPin E3_5 (Supplementary 
Figure S5). Therefore these DARPins bound to TNFR2 in 
a TNF-α-competitive manner.
TREG005 and TREG006 induce NF-κB 
signalling in Treg cells 
TNFR2 signalling promotes T cell activation by 
activating the NF-κB signalling pathway via degradation 
of inhibitor of κB (i-κB) proteins [25]. To investigate 
the potential effects of TNFR2-binding DARPins on 
T cells, human PBMCs were cultured with negative 
control DARPin E3_5 or TREG005 for 15 min, followed 
by analysis of i-κBα degradation by flow cytometry. 
Lymphocyte sub-sets were identified using mAbs specific 
for TCRαβ, CD4, CD8, CD25, CD56, and CD127. TNF-α 
was used as a positive control to induce i-κBα degradation 
in all cells via TNFR1 (Figure 3A, 3B). TREG005 induced 
degradation of i-κBα within CD4+CD25+CD127lo Treg 
cells, while effects on non-Treg cell populations were less 
pronounced and were not significant (Figures 3A, 4B). 
To a lesser extent, TREG006 also induced degradation 
of i-κBα within Treg cells (data not shown). Degradation 
of i-κBα in Treg cells in response to TNFR2-binding 
DARPins was consistent with expression of TNFR2 by 
Treg cells (Supplementary Figure S6A). Furthermore, 
using Jurkat-based reporter cells, TREG005 and TREG006 
were observed to induce NF-κB-dependent expression 
of firefly luciferase (Figure 3C). This activity depended 
on transfection to express TNFR2, and was enhanced by 
cross-linking with a polyclonal anti-human Fcγ antibody 
(data not shown), indicating TREG005 and TREG006 
are TNF-α-independent agonists which induce NF-
κB signalling by clustering TNFR2 molecules. A more 
detailed investigation into the downstream effects of 
DARPin-mediated TNFR2 signalling is on-going and will 
be reported elsewhere.
Profiling TNFR2 expression
TNFR2 expression has been widely reported for 
Treg cells and other T cell populations [26–28]. To profile 
Figure 1: Isolation of designed ankyrin repeat proteins (DARPins) which bind human Treg cells. (A) CD4+CD25+ Treg 
cells isolated from healthy donor peripheral blood mononuclear cells (PBMCs) were activated, expanded in vitro for fourteen days, and 
used for cell-binding affinity selections with a diverse library of DARPins. Output DARPins were screened for binding Treg, CD4+ Teff 
cells, and other leukocyte populations by high-throughput microscopy and flow cytometry, resulting in the isolation of thirty DARPins with 
preferential binding for human Treg cells. (B) Example data showing binding of four distinct DARPin-Fc molecules to activated Treg cells. 
(C) Median fluorescence intensity (MFI) values for DARPins binding to expanded Treg cells from two independent donors. DARPin X is 
a positive control which binds to all T cells; Off-7 is a negative control.
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TNFR2 expression, human PBMCs were cultured in 
the presence or absence of PHA-P and IL-2, and then 
stained for binding by anti-TNFR2 or control mAbs 
and a lineage panel comprising CD3, CD4, CD8, CD25, 
CD56 and Foxp3. TNFR2 was expressed by unstimulated 
CD4+Foxp3+ Treg cells, but not by other evaluated 
unstimulated lymphocyte populations (Supplementary 
Figure S6A). Following PHA-P/IL-2 stimulation, 
TNFR2 was additionally expressed by CD4+Foxp3- 
and CD8+ Teff cells, and NK cells. Next, PBMCs from 
HLA-A+ individuals with pre-determined reactivity to 
cytomegalovirus (CMV) pp65 antigen were incubated 
with pp65 peptide NLVPMVATV and profiled for TNFR2 
expression. In addition to TNFR2 expression by Treg cells, 
greater intensity expression was observed for pp65-specific 
CD8+ T cells (Supplementary Figure S6B, S6C). Of 
note, TNFR2 expression was observed for all or most 
pp65-specific CD8+ T cells (Supplementary Figure S6C, 
S6D). These data indicate that TNFR2 is expressed by 
unstimulated Treg cells, and is also expressed by activated 
Teff cells and NK cells.
Next, TNFR2 expression by tumor-infiltrating T 
cells was investigated. Expression of GITR and OX40 by 
tumor-infiltrating T cells was also investigated because, 
like TNFR2, these are co-stimulatory TNFRSF members 
which have been reported to be expressed by Treg cells 
[29]. Tumor samples from three lung cancer patients were 
analysed by flow cytometry, staining for CD19, CD3, CD4, 
CD8, Foxp3, TNFR2, GITR and OX40 (Figure 4A, 4B). 
High levels of TNFR2 expression were detected for 
CD4+Foxp3+ regulatory T cells, while lower levels were 
detected for CD4+Foxp3- and CD8+ T cells (Figure 4A, 4B). 
Similarly, the highest levels of GITR and OX40 were also 
detected for CD4+Foxp3+ Treg cells and lower levels for 
CD4+Foxp3- Teff cells. In contrast to TNFR2, very low 
or undetectable levels of GITR and OX40 were observed 
for CD8+ T cells. Together, these data indicate that 
TNFR2 is expressed by Treg and Teff cells within lung 
tumors; TNFR2 has a similar expression profile to OX40 
and GITR, and is additionally expressed by tumoral 
CD8+ T cells.
To investigate TNFR2 expression within a broader 
sample of human cancers, publicly available gene 
expression data were analysed (The Cancer Genome 
Atlas). Expression of TNFRSF1B was observed to 
correlate with CD3E expression (a marker for T cell 
infiltration of tumors) [30] for multiple tumor types, 
including bladder urothelial carcinoma, breast invasive 
carcinoma, head and neck squamous cell carcinoma, 
kidney carcinoma, lung squamous cell carcinoma, 
prostate adenocarcinoma, melanoma, and uterine corpus 
endometrial carcinoma (Supplementary Figure S7). These 
data support the hypothesis that tumor-infiltrating Treg 
and other T cells in multiple tumor types express TNFR2 
[31, 32].
Next, to profile TNFR2 expression within a pre-
clinical tumor model, immuno-competent mice were 
implanted with CT26 colorectal tumor cells. CT26 tumors 
may provide a good model for immune responses to 
tumors which are responsive to cancer immunotherapy, 
due to a high mutational burden [33]. TNFR2 expression 
was observed for CD4+Foxp3+ Treg and NKp46+ NK cells 
in all tissues examined, and was additionally observed for 
tumor-infiltrating CD4+Foxp3- and CD8+ T cells, and for 
splenic CD11b+Gr1+ myeloid cells from tumor-bearing 
animals (Figure 4). Tumor-infiltrating Treg cells expressed 
the highest levels of TNFR2. Mouse NK cell TNFR2 
expression was constant for all tissues investigated, 
and likely reflects a species difference between mice 
and humans. Together, these data indicate that TNFR2 
is expressed by Treg cells and by effector T cells in the 
context of anti-tumor immune responses.
Figure 2: Treg-binding DARPins bind to TNFR2 in a TNF-α-competitive manner. (A) Binding of TREG DARPins to 
HEK293 cells expressing TNFRSF1B, FcγRs (positive controls) or other genes (negative controls) was investigated using membrane 
protein expression arrays. (B) Bio-layer interferometry was used to investigate the interaction of immobilised TREG005 and TREG006 
with 100 nM soluble TNFR2(1-205) (solid lines) or 100 nM TNFR2(1-205) pre-incubated with 500 nM human TNF-α (dashed lines). 
Vertical dotted lines indicate transition from association to dissociation phases.
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TNFR2 mAbs enhance anti-tumor immunity in 
immuno-competent mice
The TNFR2 agonists identified by phenotypic 
screening did not cross-react with mouse TNFR2 since 
they were raised against human Treg cells. Therefore 
mouse-reactive TNFR2 agonist mAbs were sourced 
and used as surrogates to explore anti-tumor immunity 
in immuno-competent mice. Clone TR75-54.7 hamster 
anti-mouse TNFR2 mAb was previously found to 
compete with TNF-α, and to act as a TNFR2 agonist 
when cross-linked in vitro, detected by proliferation 
of the CT6 T cell-line [34]. Here, TR75-54.7 was 
confirmed to be a TNF-α-competitive TNFR2 agonist 
using bio-layer interferometry and a cell-based NF-κB 
reporter system (Supplementary Figure S8 and 
S9), therefore indicating this mAb is a suitable 
surrogate for the TNFR2-binding agonist DARPins. 
An additional anti-TNFR2 mAb (clone TR75-89) 
was investigated, which is also a TNFR2 agonist but does 
not compete with TNF-α [Supplementary Figures S8 
and S9, and 34]. There is now broad evidence that mAbs 
targeting TNFRSF members can act as agonists in vivo 
due to cross-linking by FcγR-expressing cells [35, 36]. 
Binding to recombinant mouse FcγRII and FcγRIII was 
observed for anti-TNFR2 mAbs TR75-54.7 and TR75-89, 
although no interaction with FcγRI or FcγRIV was 
observed (Supplementary Table S1), indicating these 
mAbs can be cross-linked by a sub-set of mouse FcγRs 
but should not be expected to mediate antibody-dependent 
cellular phagocytosis (ADCP).
Growth of CT26 tumors in immuno-competent mice 
was inhibited by administration of TNFR2 mAbs, compared 
to control animals which received saline or hamster IgG 
control mAbs (Figure 5A–5D). Median survival (median 
time taken to reach a consistent humane end-point based 
on tumor size) was 36 and 30.5 days after implantation for 
animals which received TR75-54.7 or TR75-89 anti-TNFR2 
mAbs, compared to 22 days or 25 days for animals which 
received saline or hamster IgG control mAb respectively 
(p < 0.0001; Figure 5E). Based on reported serum half-lives 
of approximately two days [34], approximately 90% of the 
total exposure to anti-TNFR2 mAbs occurred within ten 
days following the first dose. Therefore, the duration of 
tumor growth inhibition and enhanced survival were similar 
to the exposure to TNFR2 agonists.
Complete tumor regression was observed for two 
out of 34 animals which received anti-TNFR2 mAb TR75-
54.7, and three out of 34 animals which received TR75-89 
(Figure 5E). No tumor growth was observed when these 
animals were re-challenged with CT26 cells at least thirty 
days after tumor regression, while CT26 cells implanted 
into previously untreated control animals grew normally 
(data not shown). This indicates that TNFR2 mAbs 
induced long-lasting immunological memory against 
CT26 tumor cells.
Figure 3: TNFR2-binding DARPins induce NF-κB signalling in Treg cells. (A) Human PBMCs were incubated with 10 µg/ml 
TREG005, control DARPin E3-5 or 10 ng/ml TNF-α for 15 min, stained for lymphocyte sub-set markers and intracellular inhibitor of κBα 
(i-κBα). (B) Summary of i-κB degradation data for multiple donors (n = 10, error bars indicate SEM; significance assessed using 2-way 
ANOVA). (C) Jurkat E6.1 cells transfected to express TNFR2 and NF-κB-responsive luciferase were incubated with DARPins for 5.5 hrs, 
after which luciferase expression was assessed by luminescence (representative of three independent repeats).
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To investigate the mechanism by which TNFR2-
binding mAbs enhanced anti-tumor immunity, separate 
groups of CT26 tumor-bearing animals which received 
TNFR2 mAbs were sacrificed eighteen days after 
implantation and analysed by flow cytometry. Tumoral 
CD8+ T cell populations were greater for animals that 
received anti-TNFR2 mAbs than for controls (as a 
proportion of total tumoral CD45+ cells, Figure 5F), 
resulting in increased CD8+ T cell/Treg ratios (Figure 5G). 
No statistically significant effects on CD4+Foxp3- Teff 
cells, CD4+Foxp3+ Treg cells, CD3-NKp46+ NK cells or 
CD11b+Gr1+ myeloid cells were observed, and no effects 
were observed for any of these populations within spleens 
or tumor-draining inguinal lymph nodes (data not shown). 
Intratumoral CD8+ T cells expressed slightly higher levels 
of inducible T cell costimulator (ICOS) in response to 
TNFR2 agonist mAbs (Figure 5H), and splenic CD8+ 
T cells from mice which received TNFR2 agonist mAbs 
expressed higher levels of IFN-γ than cells from control 
animals, when stimulated with PMA/ionomycin in the 
presence of Brefeldin-A (Figure 5J).
DISCUSSION
Phenotypic screening for antibody mimetics with 
selectivity for human Treg cells has highlighted TNFR2 
as a potential therapeutic target for cancer immunotherapy. 
This approach was made possible by high purity isolation 
and in vitro expansion of human peripheral blood Treg 
cells, and through the use of DARPins, antibody mimetics 
which exhibit enhanced levels of display on phage 
[18–22]. Rapid target identification was achieved using 
membrane protein expression arrays (Figure 2A). Some 
of the TNFR2-specific DARPins were observed to induce 
i-κBα degradation in resting human Treg cells (Figure 3B), 
and to mediate NF-κB signalling in Jurkat T cells 
expressing TNFR2 (Figure 3C). The NF-κB signalling 
pathway is a key determinant of T cell activation [25], and 
has been implicated in down-regulation of Treg-mediated 
suppressive activity [37]. These observations indicate the 
potential for TNFR2-specific agonists to therapeutically 
enhance T cell-mediated immunity. 
TNFR2 expression by melanoma, colorectal cancer 
and lung cancer TILs has been reported previously [31], 
but data for expression by specific T cell sub-sets were not 
available. Here, TNFR2 expression was observed for Treg 
cells within human lung tumor samples and healthy donor 
PBMCs (Figure 4A, 4B, Supplementary Figure S6A). 
Additionally, lower intensity TNFR2 expression was 
observed for tumor-infiltrating CD4+Foxp3- and CD8+ Teff 
cells, and for PBMC-derived Teff cells following in vitro 
stimulation with PHA-P/IL-2 or specific cognate antigenic 
peptide (Supplementary Figure S6). TNFR2-binding 
DARPins were not initially observed to bind to CD3/
CD28-stimulated CD4+ Teff in the cell-based screening 
cascade (Figure 1), due to minimal TNFR2 expression by 
these cells. This may reflect a difference in the strength 
of T cell stimulation provided by anti-CD3/CD28 mAbs 
compared to other polyclonal stimuli or cognate antigenic 
stimulation. Together, these data support the idea that 
TNFR2 agonists may provide a means to therapeutically 
modulate tumoral Treg and Teff cells.
Therapeutic modulation of TNFR2 was investigated 
in mice bearing CT26 sub-cutaneous syngeneic tumors. 
Within these tumors, high levels of TNFR2 were found 
to be expressed by CD4+Foxp3+ Treg cells, with lower 
levels for CD4+Foxp3- and CD8+ T cells (Figure 4C). 
That is, a similar expression pattern was observed as for 
T cells within human NSCLC tumors. TNFR2 expression 
was also observed for splenic CD4+Foxp3+ Treg cells in 
naïve and tumor-bearing animals, and human peripheral 
blood Treg cells, confirming constitutive expression 
by Treg cells in the periphery of both species. These 
data demonstrate the relevance of the CT26 syngeneic 
tumor model for investigating TNFR2 agonists in cancer 
immunotherapy.
High-specificity binding to targets is a key 
advantage of biologics over small molecule drugs, but 
frequently also leads to a lack of cross-reactivity with non-
primate species. Hence, research within the field of cancer 
immunotherapy is frequently based on rodent-reactive 
surrogate reagents. For example, mouse-reactive anti-
CTLA-4 and anti-PD-L1 mAbs were used pre-clinically 
prior to clinical evaluation of human-reactive mAbs 
targeting these pathways [38, 39, and reviewed in 40]. 
Accordingly, a mouse-reactive TNF-α-competitive TNFR2 
agonist mAb was used here as a surrogate for the TNFR2 
agonist DARPins. This TNFR2 agonist mAb enhanced 
tumor infiltration and IFN-γ synthesis by CD8+ T cells 
in the CT26 tumor model, resulting in tumor growth 
inhibition and prolonging survival by approximately 5–15 
days (Figure 5). These data provide in vivo support for 
exploring TNFR2 agonists in cancer therapy.
Antibodies and related molecules can enhance the 
immune response to cancer either through antagonism 
of immunosuppressive molecules, such as anti-CTLA-4 
or PD-1 mAbs, through agonist activity, as previously 
described for mAbs targeting TNFRSF family members 
including GITR, OX40, CD40, and 4-1BB [41], or by 
depleting specific cell-types [42]. In principal, the TNF-α-
competitive anti-TNFR2 mAb used here could influence 
anti-tumor immune responses through blockade of TNF-α 
binding to TNFR2. However, very similar effects on tumor 
growth were observed for a different TNFR2 agonist mAb 
which does not compete with TNF-α, demonstrating 
that antagonism did not contribute appreciably to the 
therapeutic activity of the anti-TNFR2 mAbs. Similarly, 
while intra-tumoral depletion of Treg cells was recently 
found to contribute to the anti-tumor activity of CTLA-
4 mAbs in mouse models [42], intra-tumoral and splenic 
Treg populations were not significantly depleted by 
TNFR2 mAbs, and the hamster anti-TNFR2 mAbs used 
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here did not bind detectably to mouse FcγRI or FcγRIV, 
indicating these mAbs are unlikely to induce ADCP 
(Supplementary Table S1). The ability of the mouse-
reactive TNFR2 mAbs to induce TNFR2 signalling has 
been described previously [34], was confirmed here using 
in vitro reporter assays (Supplementary Figure S9), and 
is supported by the observation that these mAbs bind to, 
hence may be cross-linked by, mouse FcγRII and FcγRIII 
(Supplementary Table S1). In summary, the most likely 
mechanism for TNFR2 mAb-induced tumor growth 
inhibition is TNFR2 agonism, and associated changes in 
T cell function.
In contrast to the near-ubiquitous expression of 
TNFR1, expression of TNFR2 is confined to specific 
populations of cells including regulatory T cells, activated 
effector T cells and NK cells. TNFR2 agonist mAbs were 
observed to increase the numbers of CD8+ T within tumors, 
resulting in increased CD8+ Teff/Treg ratios, to increase the 
expression of ICOS by tumoral CD8+ T cells, and to enhance 
the level of IFN-γ synthesis by CD8+ T cells following 
ex vivo stimulation (Figure 5). Although mouse NK cells 
were observed to express TNFR2 (Figure 4), likely reflecting 
a species-specific difference between mice and humans, no 
effects on NK cell frequency or expression of activation 
markers were observed in vivo in response to TNFR2 mAbs 
(Figure 5). This suggests that TNFR2 molecules expressed 
by NK cells do not contribute towards the therapeutic 
mechanism of action for TNFR2 agonists in this model. 
Taken together, the pharmacodynamic data indicate a central 
role for CD8+ T cells in the response to TNFR2 agonists, and 
are also compatible with TNFR2-mediated down-regulation 
of Treg cell suppressive activity [37, 43].
Figure 4: TNFR2 expression within tumors. (A) Tumor samples from three lung cancer patients were analysed for expression of 
TNFR2, glucocorticoid-induced TNF-related protein (GITR), OX40 and T cell lineage markers by flow cytometry. Data shown are for 
Patient 2 in panel (B). (B) Summary of TNFR2, GITR and OX40 expression for tumor-infiltrating T cells from three lung cancer patients. 
(C) Spleens and tumors from Balb/c mice implanted sub-cutaneously with CT26 tumor cells or spleens from untreated animals were 
analysed for expression of TNFR2 and lineage markers by flow cytometry (representative of eight tumor-bearing animals and three non-
tumor-bearing animals in three independent experiments).
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TNFR2 signalling has previously been shown to 
enhance T cell activation and decrease Treg-mediated 
suppression [43–45], possibly via phosphorylation of the 
transcription factor Foxp3 [46], and via activation of the 
NF-κB signalling pathway in Treg cells [37]. Proliferation 
of adoptively transferred Ag-specific T cells in an LCMV 
glycoprotein-driven tumor model was impaired for 
TNFR2-deficient T cells [47], supporting the idea that 
Figure 5: Anti-TNFR2 mAbs inhibit tumor growth in mice. Balb/c mice were implanted with CT26 cells and following 11, 14 
and 18 days of tumor growth were injected i.p. with either (A) saline, (B) 100 μg hamster IgG control mAb, (C) 100 μg TNF-α competitor 
anti-TNFR2 mAb (clone TR75-54.7) or (D) 100 μg TNF-α non-competitor anti-TNFR2 mAb (clone TR75-89; arrows on graphs indicate 
dosing). Data for (A, B) sixteen animals per group and (C, D) 34 animals per group in two independent studies. (E) Survival of animals as 
determined by time to reach a humane end-point based on tumor size (p < 0.0001 by log-rank test). (F–J) Animals were administered anti-
TNFR2 or control mAbs on days 11 and 14 after implantation with CT26, sacrificed on day 18, and intra-tumoral lymphocytes analysed 
by flow cytometry. (F, G) Intra-tumoral CD8+ T cells and CD4+Foxp3+ Treg cells were enumerated as a proportion of tumoral CD45+ 
cells (mean +/- SEM, n = 12, p < 0.05 by 2-way ANOVA). (H) ICOS expression by CD8+ T cells (mean +/– SEM, n = 6). FMO indicates 
background staining using isotype-matched irrelevant control mAbs. (J) 18 days after tumor implantation, splenocytes were stimulated 
ex vivo with PMA/ionomycin in the presence of brefeldin-A for 5.5 hrs to assess cytokine synthesis by flow cytometry (mean +/– SEM, 
n = 6, p < 0.05 by 2-way ANOVA) 
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TNFR2 contributes to anti-tumor immunity. However, 
other reports have suggested that TNFR2 agonism could 
be detrimental towards anti-tumor immunity, either 
by inducing activation-induced cell death (AICD) of 
T cells [48, 49], or by enhancing the activation and 
suppressive activity of Treg cells [50] or myeloid-derived 
suppressor cells [51]. Inhibition of TNFR2 using anti-
sense oligonucleotide technology was observed to reduce 
experimental liver metastasis by H-59 cells in mice [52], 
and in one report, growth of syngeneic tumors in TNFR2-
deficient mice was reduced compared to wild-type animals 
[52], while in another study, tumor growth in TNFR2-
deficient animals was initially increased but at later 
time-points was reduced compared to wild-type animals 
[49]. While we cannot rule out any detrimental effects of 
TNFR2 agonism on anti-tumor immunity, overall, the net 
effect of administering TNFR2 agonist mAbs to tumor-
bearing mice was clearly to enhance anti-tumor immunity. 
Clinical evaluation of TNFR2-specific agonists 
could be performed using biologics based on DARPins 
described here, supported by previous investigational 
administration of DARPins to patients [53]. 
Alternatively, human-reactive TNFR2 agonist mAbs 
could be generated by phage display or immunisation 
approaches. We anticipate TNFR2 agonists will be most 
effective for treating tumors with a T cell-inflamed 
phenotype [54]. Publicly available data indicate a 
positive correlation between CD3E and TNFRSF1B 
expression (Supplementary Figure S7), suggesting that 
for many T cell-inflamed tumors, target expression 
may be sufficiently high to support responses to 
TNFR2-targeted therapy. In these settings, dominant 
immunological tolerance is frequently maintained 
within the tumor micro-environment by the PD-1/PD-
L1 axis. Consequently, novel immuno-oncology drugs 
are very often investigated in combination with PD-1 or 
PD-L1 blockade [12]; this is an attractive combination 
strategy for TNFR2 agonists, which should be tested 
pre-clinically prior to clinical investigation. On the basis 
of the favourable pre-clinical activity observed here 
for TNFR2 agonists, we propose that TNFR2-specific 
agonist biologics represent an attractive candidate for 
development as cancer immunotherapy drugs.
MATERIALS AND METHODS
Isolation and activation of human CD4+ Treg 
and Teff cells
Healthy donor leukapheresis samples were obtained 
from Research Blood Components (Brighton, MA) or 
the UK National Health Service Blood and Transfusion 
services (NHSBT, Addenbrooke’s Hospital, Cambridge). 
Peripheral blood mononuclear cells (PBMCs) were 
isolated by Ficoll-Paque centrifugation (GE Healthcare). 
CD4+CD25- Teff and CD4+CD25+ Treg cells were isolated 
using negative selection followed by CD25 selection 
(Dynal CD4+CD25+ Treg Kit, Invitrogen; or human CD4+ 
T cell enrichment and human CD25 positive selection 
kits, StemCell Technologies). CD4+CD25+ cells were 
cultured in X-vivo15 medium (Lonza) supplemented with 
5% human AB serum (Life Technologies), HEPES (Life 
Technologies), 1000 U/mL interleukin (IL)-2 (Roche 
Diagnostics) and 100 nM rapamycin (Sigma-Aldrich). 
Anti-CD3/CD28 beads were added (Human Treg expander 
kit, Life Technologies) at a cell:bead ratio of 1:4. Cells 
were cultured in a humidified incubator at 37°C/5% CO2 
for 7–9 days, with addition of fresh medium containing 
500 U/mL IL-2 every 2–3 days. CD3/CD28 beads 
were then removed, the cells washed and fresh medium 
containing 100 U/mL of IL-2 and 100 nM rapamycin was 
added every 2–3 days. To assess purity, cells were fixed 
and permeabilised (Foxp3/Transcription Factor Staining 
Buffer Set, eBioscience), stained using PE-conjugated 
anti-Foxp3 mAbs (clone PCH101) and analysed by 
flow cytometry (FACSCanto II, BD Biosciences). CD4+ 
effector T cells were activated using anti-CD3/CD28 beads 
(Human T-activator or Treg expander beads, Invitrogen) 
and 30 U/mL IL-2 (Roche Diagnostics) for four days.
Cell-based DARPin phage display affinity 
selections
DARPins have been described previously [19, 21]. 
Two rounds of cell-based affinity selections were each 
performed on 107 activated expanded Treg cells originating 
from seven donors using a DARPin phage display library 
containing up to 109 binding members, as described 
previously [17, 18]. The following recombinant human 
proteins were included as de-selection antigens: TCR 
α and β chains, CD5 (Cambridge Biosciences); CD69, 
CD3ε, and ITGB2 (Sino Biological); CD2 (Abcam); 
CD132, CD122, CD39, IL-10Rα, sCD4, CD109, IL-1R, 
IL-6Rα, IL-14Rα, IFN-γR1, CD45, CD38, TNFRI, 4-1BB, 
CD30, GITR, PD-1, B7-H1, CD44, CD25, CD27, and 
CD28 (R&DSystems). DARPins isolated from two rounds 
of selections were reformatted as either human IgG1 Fc 
domain fusions or mouse IgG2a Fc domain fusions and 
expressed in HEK293 cells (ATCC). 
Staining immune cells with DARPins
Mouse IgG2a DARPin-Fc fusions were initially 
screened for binding Treg and Teff cells using 8200 
Cellular Detection System (Applied Biosystems) and flow 
cytometry experiments (Figure 1 only). For subsequent 
experiments, purified human IgG1 Fc-tagged DARPins 
were used at 5 µg/mL. Where appropriate, cells were 
pre-incubated with 200 µg/mL goat anti-TNFR2 pAb 
(R&DSystems). Cells were incubated with DARPins for 
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90 min at 4°C (or in the case of titrations, on ice with 
agitation for 16 h) washed, incubated with DyLight649-
labelled goat anti-mouse or anti-human IgG pAb (Jackson 
Immunoresearch) for 45 min at 4°C and washed again. 
Alternatively, cells were incubated with unlabelled 
DARPins at a concentration of 400 µg/mL for 90 min, 
after which an equal volume containing biotinylated 
DARPins at 50 µg/mL was added without washing, the 
cells incubated for a further 45 min, washed, stained using 
APC-labelled streptavidin (eBioscience) for 45 min and 
washed again. Cells were fixed and analysed by flow 
cytometry (FACSCantoII, BD Biosciences).
Membrane protein expression arrays
Mouse IgG2a Fc-tagged DARPins were screened 
for binding to 2505 human plasma membrane proteins 
expressed in HEK293 cells using cell microarray 
technology [Retrogenix, 54]. Transfection efficiency 
was assessed by simultaneous transfection with pIRES-
hEGFR-IRES-ZsGreen1. An AlexaFluor647-labelled 
anti-mouse IgG detection antibody (Life Technologies) 
was used to detect DARPin binding. To confirm binding, 
primary hits were re-expressed in duplicate and probed 
with DARPins or a negative control mouse Fc-fusion 
protein.
ELISAs
Recombinant TNFR1, TNFR2 (R&D Systems), 
TNFR3 (LTBR, Stratech) or Osteoprotegerin 
(TNFRSF11B, Stratech) or recombinant FLAG-His10 
tagged TNFR2 ECD constructs, described in detail in 
Supplementary Materials and Methods, were immobilised 
on Maxisorb 96-well plates (Nunc). Plates were washed 
with PBS, blocked using 3% non-fat milk in PBS, then 
washed again. DARPin-Fcs or control antibodies at 
2 µg/mL in blocking solution were incubated on the plates 
for 1 h at RT. Anti-TNFR2 mIgG2a clone 22235 (R&D 
Systems), anti-His mIgG2b clone His.H8 (Millipore) and 
mIgG2b isotype control mAbs were used as controls. 
Plates were washed with PBS-Tween, then incubated with 
peroxidase-conjugated goat anti-human or anti-mouse 
IgG pAb (Sigma) in 3% non-fat milk/PBS-Tween. Plates 
were washed again with PBS-Tween and developed using 
3,3ʹ,5,5ʹ Tetramethylbenzidine (TMB) liquid substrate, 
followed by 0.5 M H2SO4, and absorption at 450 nm 
determined (Envision, Perkin Elmer).
TNF-α competition binding analyses
Recombinant human TNF-α (R&DSystems) or 
anti-mouse TNFR2 mAbs TR75-54.7 and TR75-89 
(R&DSystems) were biotinylated using EZ-Link Sulfo-
NHS-LC-biotin (Pierce) then buffer exchanged into PBS 
(Sigma) using a Zeba-Spin 7k MWCO 0.5 mL column 
(Pierce). Competition experiments were performed by 
Biolayer Interferometry (OctetRed384, ForteBio). In each 
case, one protein component (i.e. DARPin-Fc, biotinylated 
TNF-α or biotinylated anti-mouse TNFR2 mAb) was 
immobilised on either streptavidin- or protein A-coated 
Dip and Read™ biosensors (ForteBio) as appropriate (load 
step, typically 120 s), then the response was measured 
while the sensors were sequentially transferred to wells 
containing buffer only (baseline step, 60 s), ligand proteins 
± excess competitor proteins (association step, typically 
180 or 300 s), then buffer only (dissociation step, varying 
durations). Assays were performed at 25°C with 1000 rpm 
shaking, and using proteins diluted in PBS containing 
0.01% BSA 0.005% Tween-20.
i-κBα degradation assay
PBMCs were isolated from fresh whole blood 
donated by volunteers of the Cambridge BioResource 
with the approval of the Cambridge South Research 
Ethics Committee (UK). PBMCs were cryopreserved, 
defrosted, and cultured overnight in RPMI1640-based 
medium at 37°C/5% CO2. Cells were washed and 
incubated at 106 cells per mL in 500 µL medium per well, 
supplemented where appropriate with 10 ng/mL TNF-α 
or 10 µg/mL DARPins for 15 min at 37°C/5% CO2. 
Cells were re-suspended, washed once with medium, 
and stained in 100 µL per sample medium supplemented 
with membrane staining antibodies (TCRαβ-FITC clone 
IP26, CD4-PerCP-Cy5.5 clone Okt4, CD8-BV711 
clone SK1, CD56-PE-Cy7 clone HCD56, CD25-APC 
clone M-A251, CD127-BV421 clone eBioRDR5) 
for 15 min at room temperature, protected from light. 
Fixation/permeabilisation was performed according to 
manufacturer’s instructions (Introprep, Beckman Coulter). 
2 µL per sample of PE-labelled anti-ikBα (clone L35A5, 
Cell signalling) or isotype control mAbs was added, and 
the cells incubated for 15 minutes at RT, protected from 
light. Cells were washed, fixed and analysed promptly by 
flow cytometry (Fortessa, BD Biosciences).
TNFR2 signalling assays
Jurkat E6.1 cells were transfected to express 
TNFR2 and NF-κB-dependent luciferase (described in 
Supplementary Materials and Methods). 105 cells per 
well were added to opaque 96-well tissue culture plates 
(Corning) in 200 µL per well of RPMI-based medium 
supplemented with DARPins or mAbs, incubated at 
37°C/5% CO2 in a humidified incubator for 5.5 h, and 
luciferase was quantified (Steady-Glo luciferase assay, 
Promega; Envision 96-well plate reader, Perkin Elmer).
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Animal studies
Experiments were conducted using female Balb/c 
mice (Charles River) aged 8–12 weeks in accordance with 
the United Kingdom Home Office Animals (Scientific 
Procedures) Act 1986 and in accordance with EU 
Directive EU 86/609. Colorectal CT26 tumors (ATCC) 
were established by subcutaneous injection of 5 × 105 
cells in 100 µL PBS into the flank. Animal weights were 
between 18 g and 23 g on the day of implantation. Tumor 
growth was monitored using callipers, and volumes 
estimated as half the product of the length multiplied by 
the width squared.
TNFR2 expression profiling in tumor-bearing 
animals
10–12 days after tumor implantation, animals were 
sacrificed, spleens and tumors were removed. Spleens 
were disaggregated and filtered, and red blood cell lysis 
was performed (Sigma). Tumors were disaggregated 
according to manufacturer’s instructions (mouse tumor 
dissociation kit II, GentleMACS dissociator, Miltenyi 
Biotech). Cells were stained using amine-reactive dye 
(Fixable blue dead cell stain kit, Invitrogen), washed and 
stained with panels incorporating CD45-BV570 (clone 30-
F11), CD3-V450 (clone 17A2), CD4-APC (clone RM4.5), 
CD8-APC-H7 (clone 53–6.7), NKp46-EFluor450 (clone 
29A1.4), CD11b-APC (clone RM4.5), Gr1-APC-Cy7 
(clone RB6-8C5), and TNFR2-DyLight488 (clone TR75-
89), or isotype-matched control mAbs. Subsequent flow 
cytometry analysis was performed as for human cells 
except mouse-reactive Foxp3-PE mAbs were used (clone 
FJK-16S).
Investigating effects of TNFR2 mAbs in vivo
Eleven days after CT26 tumor implantation, animals 
were assigned to treatment groups by spiral randomisation 
such that all groups received an equivalent distribution 
of tumor sizes. On days 11, 14 and 18 after implantation, 
animals were injected i.p. with 100 µg of anti-TNFR2 
mAbs (clones TR75-54.7 or TR75-89, Biolegend) or 
irrelevant control mAbs (clone HTK888, Biolegend) in 
100 µL PBS. Animals were sacrificed when tumors reached 
maximum permissible size (15 mm average diameter). 
Animals in which tumors regressed completely were re-
implanted with CT26 in the contralateral flank at least 31 
days after tumors were last detectable. For flow cytometry 
analysis, animals did not receive the third dose of mAbs on 
day 18, and were instead sacrificed and organs processed as 
above. Cells were stained and analysed by flow cytometry 
as above except omitting TNFR2 staining. For cytokine 
analysis, 106 splenocytes per well were added to wells of 
96-well plates (Costar) in a volume of 200 µL RPMI1640 
(Gibco) supplemented with 10% FBS, β-mercaptoethanol 
(500 µM; Life Technologies), PMA (20 ng/mL; Sigma), 
ionomycin (1 µg/mL; Sigma) and brefeldin-A (3 µg/mL, 
Ebioscience) and incubated at 37°C/5% CO2 for 5 h, after 
which they were washed, stained with CD3-BV650 (clone 
17A2), CD4-BV785 (clone RM4-5), CD8-PerCP-Cy5.5 
(clone 53–6.7) and CD19-APC-H7 (clone 1D3) mAbs, 
fixed/permeabilised, stained with Foxp3-PacificBlue 
(clone MF1-4) and IFN-γ-APC (clone XMG1-2) mAbs, 
and analysed by flow cytometry as above.
Human lung tumor analysis
Surgical resection samples from three lung cancer 
patients were analysed by Caprion Biosciences Inc (Québec, 
Canada). This work was approved by the Comité éthique en 
recherche du Centre Hospitalier de l’Université de Montréal. 
Informed consent was obtained using informed consent 
forms. Tumors from patients 1 and 2 were adenocarcinoma 
(non-small cell lung cancer; NSCLC) and the tumor from 
Patient 3 was small cell neuroendocrine carcinoma (small 
cell lung cancer, SCLC). Briefly, tumor samples were cut 
into pieces using a scalpel, disaggregated mechanically 
(Medimachine, BD Biosciences) and stained using a 
panel including a dead cell detection reagent (Invitrogen), 
CD19-BV711 (clone HIB19), CD3-BV786 (clone SP34-
2), CD4-BV605 (clone RPA-T4), CD8-BV650 (clone 
RPA-T8), TNFR2-Alexa647 (clone hTNFR-M1), GITR-
PerCP-eFluor710 (clone eBioAITR), OX40-PE-CF594 
(clone ACT35) or appropriate isotype-matched controls, 
and Foxp3-Alexa700 (clone PCH101) mAbs or appropriate 
isotype-matched controls. Samples were analysed by flow 
cytometry (Fortessa, BD Biosciences), and data analysis 
was performed using FlowJo X.0.7 (TreeStar).
Cell-lines
All cell-lines used here were confirmed to be free 
of mycoplasma contamination using PCR, indirect Höchst 
stain and culture isolation methods (ECACC). Cell-lines 
were authenticated by short tandem repeat profiling, cell 
morphology, karyotyping, and cytochrome C oxidase I 
methods by the supplier (ATTC), and passaged for less 
than six months after resuscitation.
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